Navigation Links
Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies
Date:4/21/2009

tatements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to the risk that results from future preclinical studies and clinical trials will not correlate with the results of these preclinical studies, the risk that the fully human antibodies will not provide comparable results in combination with other cancer therapies and the risk that the Company will experience delays in enrolling patients in its existing and planned clinical studies. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008 and the quarterly report on Form 10-Q for the quarter ended January 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise an
'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
2. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
3. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
4. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
5. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
6. Studies Show Combination Laser Therapy Effective At Clearing Acne, Reducing Oil Production
7. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
8. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
9. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
10. Oridion Announces Significant Medical Studies Presented at STA
11. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... AVAX Technologies, Inc. (Pink Sheets: AVXT) ("AVAX" or ... a bridge loan financing (the "2009 Financing") pursuant ... (the "Agreement") with Firebird Global Master Fund, Ltd., ... a convertible promissory note, due June 30, 2010, ... issued a warrant to purchase an aggregate of ...
(Date:12/16/2009)... has been ranked the #1 Claims and ... 20 Best in KLAS Awards: Software & ... dynamic revenue cycle management solution providing advanced, ... and all payers. KLAS is ... performance measurement in the software, professional services, ...
(Date:12/16/2009)... Ga., Dec. 16 Greenway Medical Technologies, ... electronic health record (EHR), practice management and interoperability ... in KLAS" awards in the annual 2009 ... & Professional Services report. ,, For practices ... Chart was named Best in KLAS in ...
Breaking Medicine Technology:AVAX Technologies, Inc. Closes Bridge Financing 2AVAX Technologies, Inc. Closes Bridge Financing 3AVAX Technologies, Inc. Closes Bridge Financing 4RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 2Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 4Parents Lose Sleep Too When Students Begin School Says Atlanta Sleep Medicine Clinic 53509 1Parents Lose Sleep Too When Students Begin School Says Atlanta Sleep Medicine Clinic 53509 2Parents Lose Sleep Too When Students Begin School Says Atlanta Sleep Medicine Clinic 53509 3Parents Lose Sleep Too When Students Begin School Says Atlanta Sleep Medicine Clinic 53509 4Parents Lose Sleep Too When Students Begin School Says Atlanta Sleep Medicine Clinic 53509 5Crucial Finding Advances Spinal Cord Injury Research 53507 1Crucial Finding Advances Spinal Cord Injury Research 53507 2Hard to Treat Diseases Inc 28HTDS 29 Experiments with Hyperbaric Oxygenation 28HBO 29 Traumatic Brain Injury 53504 1Hard to Treat Diseases Inc 28HTDS 29 Experiments with Hyperbaric Oxygenation 28HBO 29 Traumatic Brain Injury 53504 2Hard to Treat Diseases Inc 28HTDS 29 Experiments with Hyperbaric Oxygenation 28HBO 29 Traumatic Brain Injury 53504 3Hard to Treat Diseases Inc 28HTDS 29 Experiments with Hyperbaric Oxygenation 28HBO 29 Traumatic Brain Injury 53504 4
... Development Milestone ... Technology, IRVING, Texas, Aug. 15 Carrington,Laboratories, Inc. ... Inc. has initiated the animal toxicology studies of its,GelVac(TM) ... The toxicology studies are a critical step during ...
... Early Investment by Cystic Fibrosis ... ... one of the world,s largest biopharmaceutical companies, and Parion,Sciences, Inc., a ... that could become an important,new drug in treating the basic defect ...
Other Medicine Technology:Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine 2Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine 3Promising Cystic Fibrosis Compound on Track for Development 2
(Date:12/17/2009)... from MediNiche provide alternative natural relief prior to considering drugs. ... ... December 17, 2009 -- D-Psoria products are the ... associated with severe skin conditions . Developed by ... by MediNiche Pharmaceuticals, St. Louis, Missouri., , ,D-Psoria ...
(Date:12/17/2009)... complex personal injury and insurance cases, recognized for exceptional appellate work ... ... Nexis) December 17, 2009 -- Jody Nathan , a respected ... injury and insurance coverage disputes, has been named by Oklahoma Super ... of Oklahoma for 2009-2010., , ,Only five percent of the lawyers ...
(Date:12/16/2009)... Dec. 17 Health care sector revenue ... trillion, up from $1.66 trillion in 2007, according ... This sector is classified under the North American ... http://www.newscom.com/cgi-bin/prnh/20090226/CENSUSLOGO ) ,, These figures come from ... and Social Assistance , a series of tables ...
(Date:12/16/2009)... Dec. 16 New Enterprise Associates, Inc. ... announced that one of its portfolio companies, Acclarent, ... be acquired by Ethicon, Inc., a Johnson & ... $785 million (net of estimated cash on hand ... dedicated to designing, developing and commercializing devices that ...
(Date:12/16/2009)... WASHINGTON, Dec. 16 Losing has never felt ... knows maintaining his healthy new lifestyle means continuing to ... Drinking fat free milk is one healthy choice that ... a simple step everyone can take. Every glass of ... muscle, potassium to help maintain normal blood pressure, and ...
Breaking Medicine News(10 mins):Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 2Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 3Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 4Health News:Jody Nathan, Highly Regarded Tulsa Attorney, Named to 2009 Oklahoma Super Lawyers List 2Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 2Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 3Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3
... developed at the University at Buffalo has killed every ... airborne spores, viruses and bacteria in independent tests conducted ... prototype produced by Buffalo BioBlower Technologies LLC, a UB ... better than one part per million in an independent ...
... Dental Experts to Advance ... of CCLAD in Dentistry, LIVINGSTON, N.J., Feb. 28 ... leader in,advanced injection technologies, today reported that earlier this ... (CCLAD) Summit in New Orleans. The Summit welcomed a ...
... Out of Poverty on Average Pays,for Itself and ... LOS ANGELES, Feb. 28 Close to ... today at the Milken,Institute for the West Coast ... the United States economy through proven,investments in children. ...
... motivates people to stay active, helps reduce arthritis ... pain ... announced today a,partnership with McNeil Consumer Healthcare, the maker of TYLENOL(R),Arthritis ... and reduce arthritis pain. Through this new collaboration,participating YMCAs will introduce ...
... was issued by The Mesothelioma Applied Research, Foundation ... House, Energy and Commerce Committee on the "Bruce Vento ... Thursday, February 28, 2008. The Meso,Foundation is urging the ... step-up to the plate in allocating research funds for ...
... Commission Director General for Enterprise & Industry Heinz Zourek today ... an EC budget of 624 million to ESA as a ... , This will be provided in two stages: 419 million ... the GSC programme. Segment 2 will be submitted for subscription ...
Other Medicine News:Health News:UB's bioblower closer to protecting soldiers from biological attack 2Health News:UB's bioblower closer to protecting soldiers from biological attack 3Health News:Milestone Scientific Hosts First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit 2Health News:Milestone Scientific Hosts First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit 3Health News:Milestone Scientific Hosts First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit 4Health News:Milestone Scientific Hosts First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit 5Health News:Business Leaders, Policy Makers and Advocates Gather to Discuss Strategies for Securing the Nation's Economy by Investing in Early Childhood 2Health News:Business Leaders, Policy Makers and Advocates Gather to Discuss Strategies for Securing the Nation's Economy by Investing in Early Childhood 3Health News:YMCA of the USA and McNeil Consumer Healthcare Partner to Promote Health for Older Adults 2Health News:YMCA of the USA and McNeil Consumer Healthcare Partner to Promote Health for Older Adults 3Health News:Leading Asbestos-Cancer Group Urges Congress to Partner with Them and Support Funding Provisions in Asbestos Ban Legislation 2Health News:Leading Asbestos-Cancer Group Urges Congress to Partner with Them and Support Funding Provisions in Asbestos Ban Legislation 3Health News:Space sentinels: New 'tools' in space to improve European environment and security policies 2Health News:Space sentinels: New 'tools' in space to improve European environment and security policies 3
Angulated, blunt tips....
Extended modified needle - 25/box....
... Loop and Square electrodes feature ... and integrity throughout the excision ... 3/32" (2.3 mm) shaft. All ... a patented protective tray to ...
400 Series Monopolar Foot Activated Forceps...
Medicine Products: